Literature DB >> 11123087

Clinical value of antineutrophil cytoplasmic antibodies.

V Rus1, B S Handwerger.   

Abstract

This article presents a brief review of the clinical value of antineutrophil cytoplasmic antibodies (ANCA) in the diagnosis and management of patients with various forms of vasculitis. ANCA assay methodology and testing recommendations are reviewed. The patterns of reactivity of ANCA observed by indirect immunofluorescence, the antigens recognized by ANCA, and the sensitivity, specificity, and positive predictive value of ANCA for diagnosis of different vasculitides are described. In addition, the spectrum of drugs and nonvasculitic diseases that are associated with ANCA and need to be differentiated from true ANCA-positive vasculitides are reviewed. When properly utilized and cautiously interpreted, ANCA are a useful, noninvasive diagnostic tool in the differential diagnosis of vasculitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123087     DOI: 10.1007/s11926-000-0037-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  44 in total

1.  Antimyeloperoxidase antibodies in the Churg-Strauss syndrome.

Authors:  J W Tervaert; R Goldschmeding; J D Elema; A E von dem Borne; C G Kallenberg
Journal:  Thorax       Date:  1991-01       Impact factor: 9.139

Review 2.  Drugs associated with vasculitis.

Authors:  P A Merkel
Journal:  Curr Opin Rheumatol       Date:  1998-01       Impact factor: 5.006

3.  Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis.

Authors:  G S Kerr; T A Fleisher; C W Hallahan; R Y Leavitt; A S Fauci; G S Hoffman
Journal:  Arthritis Rheum       Date:  1993-03

4.  Association of autoantibodies to myeloperoxidase with different forms of vasculitis.

Authors:  J W Tervaert; R Goldschmeding; J D Elema; P C Limburg; M van der Giessen; M G Huitema; M I Koolen; R J Hené; T H The; G K van der Hem
Journal:  Arthritis Rheum       Date:  1990-08

5.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.

Authors:  E C Hagen; M R Daha; J Hermans; K Andrassy; E Csernok; G Gaskin; P Lesavre; J Lüdemann; N Rasmussen; R A Sinico; A Wiik; F J van der Woude
Journal:  Kidney Int       Date:  1998-03       Impact factor: 10.612

6.  Anti-myeloperoxidase autoantibodies in patients with necrotizing glomerular and alveolar capillaritis.

Authors:  X Bosch; E Mirapeix; J Font; R Cervera; M Ingelmo; M A Khamashta; L Revert; G R Hughes; A Urbano-Márquez
Journal:  Am J Kidney Dis       Date:  1992-09       Impact factor: 8.860

7.  Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies.

Authors:  C Franssen; R Gans; C Kallenberg; C Hageluken; S Hoorntje
Journal:  J Intern Med       Date:  1998-09       Impact factor: 8.989

8.  Anti-neutrophil cytoplasmic antibodies (ANCA) in myelodysplasia and other haematological disorders.

Authors:  J A Savige; L Chang; C L Smith; J C Duggan
Journal:  Aust N Z J Med       Date:  1994-06

9.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

Authors:  R J Falk; J C Jennette
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

10.  Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease.

Authors:  C F Franssen; R O Gans; B Arends; C Hageluken; P M ter Wee; P G Gerlag; S J Hoorntje
Journal:  Kidney Int       Date:  1995-01       Impact factor: 10.612

View more
  1 in total

1.  A girl with microscopic polyangiitis: an unexpected clinical course with long-term follow-up.

Authors:  Selcuk Yuksel; Fatos Yalcinkaya; Zeynep Birsin Ozcakar; Banu Acar; Ozden Tulunay; Mesiha Ekim
Journal:  Pediatr Nephrol       Date:  2005-05       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.